1587 related articles for article (PubMed ID: 28549077)
21. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease.
Caspell-Garcia C; Simuni T; Tosun-Turgut D; Wu IW; Zhang Y; Nalls M; Singleton A; Shaw LA; Kang JH; Trojanowski JQ; Siderowf A; Coffey C; Lasch S; Aarsland D; Burn D; Chahine LM; Espay AJ; Foster ED; Hawkins KA; Litvan I; Richard I; Weintraub D;
PLoS One; 2017; 12(5):e0175674. PubMed ID: 28520803
[TBL] [Abstract][Full Text] [Related]
22. Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease.
Zeighami Y; Fereshtehnejad SM; Dadar M; Collins DL; Postuma RB; Dagher A
Neuroimage Clin; 2019; 24():101986. PubMed ID: 31514113
[TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
[TBL] [Abstract][Full Text] [Related]
24. Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.
Buongiorno M; Antonelli F; Compta Y; Fernandez Y; Pavia J; Lomeña F; Ríos J; Ramírez I; García JR; Soler M; Cámara A; Fernández M; Basora M; Salazar F; Sanchez-Etayo G; Valldeoriola F; Barrio JR; Marti MJ
J Alzheimers Dis; 2017; 55(3):1261-1272. PubMed ID: 27814297
[TBL] [Abstract][Full Text] [Related]
25. Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment.
Pyun JM; Park YH; Kim HR; Suh J; Kang MJ; Kim BJ; Youn YC; Jang JW; Kim S;
Alzheimers Res Ther; 2017 Dec; 9(1):99. PubMed ID: 29246250
[TBL] [Abstract][Full Text] [Related]
26. Machine learning-based prediction of longitudinal cognitive decline in early Parkinson's disease using multimodal features.
Almgren H; Camacho M; Hanganu A; Kibreab M; Camicioli R; Ismail Z; Forkert ND; Monchi O
Sci Rep; 2023 Aug; 13(1):13193. PubMed ID: 37580407
[TBL] [Abstract][Full Text] [Related]
27. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally.
Hanganu A; Bedetti C; Degroot C; Mejia-Constain B; Lafontaine AL; Soland V; Chouinard S; Bruneau MA; Mellah S; Belleville S; Monchi O
Brain; 2014 Apr; 137(Pt 4):1120-9. PubMed ID: 24613932
[TBL] [Abstract][Full Text] [Related]
28. Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson's disease.
Madhyastha TM; Askren MK; Zhang J; Leverenz JB; Montine TJ; Grabowski TJ
Brain; 2015 Sep; 138(Pt 9):2672-86. PubMed ID: 26173859
[TBL] [Abstract][Full Text] [Related]
29. Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease.
De Pablo-Fernández E; Lees AJ; Holton JL; Warner TT
JAMA Neurol; 2019 Apr; 76(4):470-479. PubMed ID: 30640364
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
Sierra-Rio A; Balasa M; Olives J; Antonell A; Iranzo A; Castellví M; Bosch B; Grau-Rivera O; Fernandez-Villullas G; Rami L; Lladó A; Sánchez-Valle R; Molinuevo JL
Neurodegener Dis; 2016; 16(1-2):69-76. PubMed ID: 26560503
[TBL] [Abstract][Full Text] [Related]
31. The combined effect of REM sleep behavior disorder and hyposmia on cognition and motor phenotype in Parkinson's disease.
Kang SH; Lee HM; Seo WK; Kim JH; Koh SB
J Neurol Sci; 2016 Sep; 368():374-8. PubMed ID: 27538667
[TBL] [Abstract][Full Text] [Related]
32. [Subtypes of mild cognitive impairment in Parkinson's disease and factors predicting its becoming dementia].
Toribio-Diaz ME; Carod-Artal FJ
Rev Neurol; 2015 Jul; 61(1):14-24. PubMed ID: 26108904
[TBL] [Abstract][Full Text] [Related]
33. Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline.
Ten Kate M; Dicks E; Visser PJ; van der Flier WM; Teunissen CE; Barkhof F; Scheltens P; Tijms BM;
Brain; 2018 Dec; 141(12):3443-3456. PubMed ID: 30351346
[TBL] [Abstract][Full Text] [Related]
34. Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study.
Joza S; Hu MT; Jung KY; Kunz D; Stefani A; Dušek P; Terzaghi M; Arnaldi D; Videnovic A; Schiess MC; Hermann W; Lee JY; Ferini-Strambi L; Lewis SJG; Leclair-Visonneau L; Oertel WH; Antelmi E; Sixel-Döring F; Cochen De Cock V; Liguori C; Liu J; Provini F; Puligheddu M; Nicoletti A; Bassetti CLA; Bušková J; Dauvilliers Y; Ferri R; Montplaisir JY; Lawton M; Kim HJ; Bes F; Högl B; Šonka K; Fiamingo G; Mattioli P; Lavadia ML; Suescun J; Woo KA; Marelli S; Martens KE; Janzen A; Plazzi G; Mollenhauer B; Fernandes M; Li Y; Cortelli P; Figorilli M; Cicero CE; Schaefer C; Guiraud L; Lanza G; Gagnon JF; Sunwoo JS; Ibrahim A; Girtler N; Trenkwalder C; Baldelli L; Pelletier A; Postuma RB;
Brain; 2023 Aug; 146(8):3258-3272. PubMed ID: 36881989
[TBL] [Abstract][Full Text] [Related]
35. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
Delgado-Alvarado M; Dacosta-Aguayo R; Navalpotro-Gómez I; Gago B; Gorostidi A; Jiménez-Urbieta H; Quiroga-Varela A; Ruiz-Martínez J; Bergareche A; Rodríguez-Oroz MC
Mov Disord; 2018 Nov; 33(11):1809-1813. PubMed ID: 30423201
[TBL] [Abstract][Full Text] [Related]
36. Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-β Status in Parkinson's disease-Related Cognitive Decline.
Labrador-Espinosa MA; Silva-Rodríguez J; Reina-Castillo MI; Mir P; Grothe MJ
Mov Disord; 2023 Oct; 38(10):1871-1880. PubMed ID: 37492892
[TBL] [Abstract][Full Text] [Related]
37. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
[TBL] [Abstract][Full Text] [Related]
38. Diffusion and structural MRI as potential biomarkers in people with Parkinson's disease and cognitive impairment.
Huang CC; Chen PH; Tsai CC; Chiang HF; Hsieh CC; Chen TL; Liao WH; Chen YL; Wang JJ
Eur Radiol; 2024 Jan; 34(1):126-135. PubMed ID: 37572194
[TBL] [Abstract][Full Text] [Related]
39. Body side and predominant motor features at the onset of Parkinson's disease are linked to motor and nonmotor progression.
Baumann CR; Held U; Valko PO; Wienecke M; Waldvogel D
Mov Disord; 2014 Feb; 29(2):207-13. PubMed ID: 24105646
[TBL] [Abstract][Full Text] [Related]
40. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.
Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P;
BMC Neurol; 2016 Feb; 16():26. PubMed ID: 26911448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
